Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

Abstract Background The short-term efficacy of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) has been demonstrated across several phase 3 trials, while the ADPKD Outcomes Model (ADPKD-OM) represents a validated approach to predict natural disease progression over a...

Full description

Bibliographic Details
Main Authors: Hayley Bennett, Phil McEwan, Karina Hamilton, Karl O’Reilly
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Nephrology
Subjects:
Autosomal dominant polycystic kidney disease
Disease modelling
Tolvaptan
End-stage renal disease
Renal function decline
Online Access:http://link.springer.com/article/10.1186/s12882-019-1290-5

Internet

http://link.springer.com/article/10.1186/s12882-019-1290-5

Similar Items